Android app Apple app link

Novo gains Lexicon obesity drug; CRISPR COO to step down

By Yahoo! Finance   |   2 weeks ago
Novo gains Lexicon obesity drug; CRISPR COO to step down

Stay updated on Novo Nordisk, DBV Technologies, Arbutus Biopharma, Bicycle Therapeutics, and CRISPR Therapeutics news. Novo Nordisk licensed LX9851 from Lexicon Pharmaceuticals for obesity treatment. DBV Technologies secured funding for its peanut allergy skin patch.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.